Matches in SemOpenAlex for { <https://semopenalex.org/work/W2895024254> ?p ?o ?g. }
Showing items 1 to 86 of
86
with 100 items per page.
- W2895024254 abstract "Abstract Background Carbapenem-nonsusceptible Enterobacteriaceae (CRE) are often multidrug-resistant and infections caused by these organisms are associated with increased morbidity and mortality. The combination of avibactam (AVI), a non-β-lactam/β-lactamase inhibitor of Class A, C, and some D serine β-lactamases, with ceftazidime (CAZ) and aztreonam (ATM) is being developed to treat infections caused by CRE. CAZ-AVI reveals potent in vitro activity against CRE, except those producing metallo-β-lactamases (MBLs), whereas ATM-AVI inhibits growth of both MBL-positive and MBL-negative CRE. We evaluated the in vitro activity of CAZ-AVI and ATM-AVI against Enterobacteriaceae isolates nonsusceptible to meropenem (MEM-NS) collected in 2014–2017 in Latin America through the INFORM global surveillance program. Methods Nonduplicate clinically significant isolates were collected from 29 hospital laboratories located in Argentina, Brazil, Chile, Colombia, Mexico, and Venezuela. Susceptibility testing was performed by CLSI broth microdilution. AVI was tested at a fixed concentration of 4 µg/mL in combination with CAZ and ATM. MEM-NS Eba (MIC >1 µg/mL) were screened for the presence of β-lactamase genes by PCR and sequencing. Results Five hundred fifty-seven MEM-NS isolates were identified (440 Klebsiella pneumoniae and 117 isolates of 13 other species). Of these, 441 (79.2%) carried carbapenemases (Cpase) (KPC only, n = 383; MBL only, n = 48; OXA-48-like only, n = 5; KPC and OXA-48-like, n = 2; MBL and GES, n = 2; MBL and KPC, n = 1). CAZ-AVI showed potent in vitro activity against Cpase-positive MBL-negative and Cpase-negative Eba and against all MEM-NS Eba, but was not active against MBL-positive Eba. 100% of MEM-NS Eba were inhibited by ≤8 µg/mL of ATM-AVI. Conclusion CAZ-AVI and ATM-AVI displayed potent in vitro activity against MEM-NS Eba collected in LA. These agents could serve as promising options for treatment of infections caused by CRE. Disclosures K. Kazmierczak, Pfizer Inc.: Consultant, Consulting fee. IHMA, Inc.: Employee, Salary. B. De Jonge, AstraZeneca: Shareholder, Dividends. Pfizer Inc: Employee, Salary. G. G. Stone, Pfizer Inc.: Employee, Salary. AstraZeneca: Former Employee and Shareholder, Salary. D. Sahm, Pfizer Inc.: Consultant, Consulting fee. IHMA, Inc.: Employee, Salary." @default.
- W2895024254 created "2018-10-12" @default.
- W2895024254 creator A5019416826 @default.
- W2895024254 creator A5020992600 @default.
- W2895024254 creator A5027534791 @default.
- W2895024254 creator A5066677972 @default.
- W2895024254 date "2018-11-01" @default.
- W2895024254 modified "2023-09-26" @default.
- W2895024254 title "1372. In Vitro Activity of Novel Ceftazidime–Avibactam and Aztreonam–Avibactam Combinations Against Carbapenem-Nonsusceptible Enterobacteriaceae Isolates by Phenotype Collected in Latin America From 2014 to 2017 as Part of the INFORM Surveillance Program" @default.
- W2895024254 doi "https://doi.org/10.1093/ofid/ofy210.1203" @default.
- W2895024254 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6253086" @default.
- W2895024254 hasPublicationYear "2018" @default.
- W2895024254 type Work @default.
- W2895024254 sameAs 2895024254 @default.
- W2895024254 citedByCount "0" @default.
- W2895024254 crossrefType "journal-article" @default.
- W2895024254 hasAuthorship W2895024254A5019416826 @default.
- W2895024254 hasAuthorship W2895024254A5020992600 @default.
- W2895024254 hasAuthorship W2895024254A5027534791 @default.
- W2895024254 hasAuthorship W2895024254A5066677972 @default.
- W2895024254 hasBestOaLocation W28950242541 @default.
- W2895024254 hasConcept C104317684 @default.
- W2895024254 hasConcept C176947019 @default.
- W2895024254 hasConcept C202751555 @default.
- W2895024254 hasConcept C2775933652 @default.
- W2895024254 hasConcept C2775992322 @default.
- W2895024254 hasConcept C2776685102 @default.
- W2895024254 hasConcept C2776968632 @default.
- W2895024254 hasConcept C2777058267 @default.
- W2895024254 hasConcept C2777406300 @default.
- W2895024254 hasConcept C2777637488 @default.
- W2895024254 hasConcept C2778910516 @default.
- W2895024254 hasConcept C2779375183 @default.
- W2895024254 hasConcept C2779631663 @default.
- W2895024254 hasConcept C2780416669 @default.
- W2895024254 hasConcept C2780950330 @default.
- W2895024254 hasConcept C501593827 @default.
- W2895024254 hasConcept C523546767 @default.
- W2895024254 hasConcept C54355233 @default.
- W2895024254 hasConcept C547475151 @default.
- W2895024254 hasConcept C71924100 @default.
- W2895024254 hasConcept C86803240 @default.
- W2895024254 hasConcept C89423630 @default.
- W2895024254 hasConcept C94665300 @default.
- W2895024254 hasConceptScore W2895024254C104317684 @default.
- W2895024254 hasConceptScore W2895024254C176947019 @default.
- W2895024254 hasConceptScore W2895024254C202751555 @default.
- W2895024254 hasConceptScore W2895024254C2775933652 @default.
- W2895024254 hasConceptScore W2895024254C2775992322 @default.
- W2895024254 hasConceptScore W2895024254C2776685102 @default.
- W2895024254 hasConceptScore W2895024254C2776968632 @default.
- W2895024254 hasConceptScore W2895024254C2777058267 @default.
- W2895024254 hasConceptScore W2895024254C2777406300 @default.
- W2895024254 hasConceptScore W2895024254C2777637488 @default.
- W2895024254 hasConceptScore W2895024254C2778910516 @default.
- W2895024254 hasConceptScore W2895024254C2779375183 @default.
- W2895024254 hasConceptScore W2895024254C2779631663 @default.
- W2895024254 hasConceptScore W2895024254C2780416669 @default.
- W2895024254 hasConceptScore W2895024254C2780950330 @default.
- W2895024254 hasConceptScore W2895024254C501593827 @default.
- W2895024254 hasConceptScore W2895024254C523546767 @default.
- W2895024254 hasConceptScore W2895024254C54355233 @default.
- W2895024254 hasConceptScore W2895024254C547475151 @default.
- W2895024254 hasConceptScore W2895024254C71924100 @default.
- W2895024254 hasConceptScore W2895024254C86803240 @default.
- W2895024254 hasConceptScore W2895024254C89423630 @default.
- W2895024254 hasConceptScore W2895024254C94665300 @default.
- W2895024254 hasLocation W28950242541 @default.
- W2895024254 hasLocation W28950242542 @default.
- W2895024254 hasLocation W28950242543 @default.
- W2895024254 hasOpenAccess W2895024254 @default.
- W2895024254 hasPrimaryLocation W28950242541 @default.
- W2895024254 hasRelatedWork W2558629325 @default.
- W2895024254 hasRelatedWork W2755901612 @default.
- W2895024254 hasRelatedWork W2887566059 @default.
- W2895024254 hasRelatedWork W2895024254 @default.
- W2895024254 hasRelatedWork W2981333838 @default.
- W2895024254 hasRelatedWork W3094904356 @default.
- W2895024254 hasRelatedWork W3111122494 @default.
- W2895024254 hasRelatedWork W3126415404 @default.
- W2895024254 hasRelatedWork W3175780706 @default.
- W2895024254 hasRelatedWork W4248329483 @default.
- W2895024254 isParatext "false" @default.
- W2895024254 isRetracted "false" @default.
- W2895024254 magId "2895024254" @default.
- W2895024254 workType "article" @default.